A complete R&D system for biological preparations for diseases such as metabolism and ophthalmology has been established. Upstream target screening: GLP1R, PTH1R, VEGF, ANG2 with multi-disease multi-body modular library. Midstream optimization platform: including antibody humanization, affinity maturation, and high expression level. Downstream biological preparations: stable platform at room temperature, sustained and controlled release platform, biological activity detection technology platform, etc. At the same time, the Group has also established our own platform in the field of new antibodies such as bispecific antibodies and nanobodies, and has gradually enriched and improved the R&D pipeline of new antibodies to provide more innovative drugs for disease treatment.